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Abstract
Scavenger receptors constitute a large family of proteins that are structurally diverse and 
participate in a wide range of biological functions. These receptors are expressed predominantly 
by myeloid cells and recognize a diverse variety of ligands including endogenous and modified 
host-derived molecules and microbial pathogens. There are currently eight classes of scavenger 
receptors, many of which have multiple names, leading to inconsistencies and confusion in the 
literature. To address this problem, a workshop was organized by the United States National 
Institute of Allergy and Infectious Diseases, National Institutes of Health, to help develop a clear 
definition of scavenger receptors and a standardized nomenclature based on that definition. Fifteen 
experts in the scavenger receptor field attended the workshop and, after extensive discussion, 
reached a consensus regarding the definition of scavenger receptors and a proposed scavenger 
receptor nomenclature. Scavenger receptors were defined as cell surface receptors that typically 
bind multiple ligands and promote the removal of nonself or altered-self targets. They often 
function by mechanisms that include endocytosis, phagocytosis, adhesion, and signaling that 
PrabhuDas et al. Page 2
J Immunol. Author manuscript; available in PMC 2017 November 15.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
ultimately lead to the elimination of degraded or harmful substances. Based on this definition, 
nomenclature and classification of these receptors into 10 classes were proposed. This 
classification was discussed at three national meetings and input from participants at these 
meetings was requested. The following manuscript is a consensus statement that combines the 
recommendations of the initial workshop and incorporates the input received from the participants 
at the three national meetings.
Scavenger receptor activity was first described by Drs. Brown and Goldstein (1) when they 
identified receptors in macrophages that endocytosed and degraded modified (acetylated), 
but not native, low-density lipoprotein (LDL). Drs. Brown and Goldstein showed that these 
receptors for acetylated LDL recognized a wide variety of polyanionic ligands (2). 
Purification and cloning of the corresponding receptor protein and cDNA (3, 4) was soon 
followed by the identification of other modified LDL receptors (LDLRs) with broad binding 
specificity. In an initial attempt to systematically categorize these receptors, M. Krieger 
proposed to subdivide them into “classes” (A, B, etc.) based on their sequences, and each 
class subdivided further into “types” based on additional variations in their sequences due to 
alternative splicing (5).
There are currently eight classes of scavenger receptors (classes A–H). In some cases, 
multiple names have been assigned to the same receptor (e.g., MSR1, SR-AI, CD204, and 
SCARA1). In addition, there are proteins exhibiting scavenger receptor activity that have 
been named based on other criteria and have not been included in a general scavenger 
receptor nomenclature. Some examples include RAGE, LRP1, LRP2, ASGP, CD163, SR-
PSOX, and CXCL16. New scavenger receptors also continue to be discovered and identified 
(6, 7). Therefore, it is important to convey consistent understanding and minimize 
redundancy and miscommunication in the scavenger receptor field. Developing a 
standardized nomenclature has the benefit of decreasing redundancy and facilitating 
communication and collaboration among investigators within a field, as well as in different 
fields, by building on a common understanding. Efforts to standardize other scientific 
nomenclatures have occurred in areas such as chemokines and their receptors (8), TNF 
family of receptors involved in bone metabolism (9), complement peptide receptors (10), 
and glutamate receptors (11). Committees, such as the International Union of Basic and 
Clinical Pharmacology, formed specifically for these processes by scientific societies or 
investigators in the field have developed systematic nomenclatures, for example, http://
www.guidetopharmacology.org/nomenclature.jsp (accessed April 10, 2016), within each 
field for adoption by the broader scientific community.
To address the lack of a unified nomenclature system for scavenger receptors and better 
organize the field, the United States National Institute of Allergy and Infectious Diseases 
(NIAID), at the National Institutes of Health (NIH), represented by M.R. PrabhuDas, 
initiated discussions with J. El Khoury and Dr. Siamon Gordon which led to organizing and 
convening a workshop in which 15 investigators from five countries proposed a consensus 
definition of scavenger receptors and a systematic, standard nomenclature. The workshop 
participants and their areas of expertise are listed in Table I.
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The objectives of this workshop were to: 1) establish guidelines and recommendations for 
standardizing the nomenclature for scavenger receptors; 2) consider strategies for dealing 
with future discoveries of scavenger receptors; and 3) communicate the recommendations to 
the wider scientific community as a point of reference and for further discussion and final 
scavenger receptor nomenclature standardization. The discussion and nomenclature 
recommendations described herein only refer to mammalian scavenger receptors.
Scavenger receptor background and history
The original description of scavenger receptors was in the context of studies of lipoproteins, 
atherosclerosis, and familial hypercholesterolemia (1, 12). Drs. Michael Brown and Joseph 
Goldstein (1) had previously identified LDLRs and LDLR-mediated endocytosis and 
established that familial hypercholesterolemia was caused by loss-of-function mutations in 
the LDLRs, which led to increased plasma LDL, premature atherosclerosis, and heart 
disease (1). Analysis of familial hypercholesterolemia patients showed that plasma LDL 
could be cleared by an LDLR-independent pathway called the “scavenger pathway.” The 
earliest use of the term “scavenger receptor” to refer to the broad specificity receptor 
identified by Dr. Brown and Dr. Goldstein was in 1981 by Fogelman and colleagues (13).
The first receptors that carried the name “scavenger receptor” were purified in 1988 (14) and 
cloned in 1990 (15, 16) by the Krieger group and were found to be alternatively spliced gene 
products of a single gene which were initially named type I and type II macrophage 
scavenger receptors. When additional scavenger receptors were identified, the type I and II 
macrophage receptors were renamed scavenger receptor, class A, type I and type II (SR-AI 
and SR-AII) by the Krieger group. One distinct feature of the broad binding specificity of 
scavenger receptors was that they could recognize a large repertoire of ligands, ranging from 
bacteria and yeast to self (native proteins) and modified-self targets (2, 17–21). Besides 
playing a role in host defense, class A scavenger receptors have been shown to be involved 
in functions such as homeostasis, Ag presentation, and pathogenesis of neurodegenerative 
disorders (22, 23).
Based on their broad ligand-binding specificities and expression in macrophages, Krieger 
and colleagues (5) proposed that scavenger receptors could serve as pattern recognition 
receptors for innate immunity. Work done by groups led by Drs. S. Gordon, M. Krieger, K. 
Joiner, T. Kodama, and J. El Khoury provided direct evidence that the class A receptors are 
adhesion receptors, and that they recognize Gram-positive bacteria and β-amyloid, 
confirming the broad ligand specificity for these receptors (17, 24, 25). Additional members 
of the class A scavenger receptors such as MARCO (26) and SCARA5 (27) were 
subsequently identified and demonstrated a role in homeostasis, adhesion, and cancer 
progression (28). Other multiligand pattern recognition receptors were independently 
identified, including CD14 (29), mannose receptors (30), and CD36 (31).
A report that served as an initial step in presenting the proposed nomenclature to the 
research community was published in The Journal of Immunology (32). A Web site was set 
up to invite comments from fellow investigators in response to the proposed nomenclature. 
The Web site (https://respond.niaid.nih.gov/ScavengerReceptors/) was open for three months 
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for public comment. In addition, NIAID organized several follow-up sessions at the 
following national meetings: Experimental Biology 2014 in San Diego, CA (http://
experimentalbiology.org/2014/Home.aspx), Immunology 2014 in Pittsburgh, PA (http://
www.immunology2014.org/), and Federation of Clinical Immunology Societies (FOCIS 
2014) in Chicago, IL (http://www.focisnet.org/focis-2014). The sessions were open to the 
attendees of these national meetings to provide the broader scientific community with the 
opportunity to provide their comments and recommendations on the proposed scavenger 
receptor nomenclature. We now incorporate the comments received at the three national 
meetings and present a unified, consensus, and definitive classification and nomenclature for 
scavenger receptors.
Scavenger receptor nomenclature recommendations
At the initial workshop convened by the NIH, participants developed a definition of 
scavenger receptors, incorporating the various facets and characteristics of these receptors. 
This definition was used as the benchmark against which proposed nomenclatures were 
considered. As mentioned above, scavenger receptors were originally defined as cell surface 
proteins that bound chemically modified lipoproteins with high affinity. Additional 
characteristics included the ability to bind multiple ligands (broad-binding specificity), 
mediate endocytosis, in some cases mediate signaling, and act as innate immune pattern 
recognition receptors.
Based on the discussion, the group agreed upon the following working definition for 
scavenger receptors: Scavenger receptors are cell surface receptors that typically bind 
multiple ligands and promote the removal of nonself or altered-self targets. They often 
function by mechanisms that include endocytosis, phagocytosis, adhesion, and signaling that 
ultimately lead to the elimination of degraded or harmful substances.
Fig. 1 illustrates the consensus nomenclature formula agreed upon at the initial meeting. As 
an example, a scavenger receptor belonging to class A will be designated as SR-A1, where 
SR stands for scavenger receptor and is followed by a hyphen, then a capital letter 
representing the class of scavenger receptor, then an Arabic numeral representing the type of 
molecule within the class. Alternate splice variants are designated by a dot and an Arabic 
numeral following the type of molecule within the class (e.g., SR-A1.1). The numbering is 
based on the order in which the molecules were identified.
In the three follow up meetings there were discussions regarding the definition. There were 
questions as to whether receptors that strictly bind only pathogens should be included. The 
examples given were for viral receptors for rhinovirus or severe acute respiratory syndrome 
(SARS) (ICAM-1 or ACE2, respectively). There was also discussion on whether binding to 
modified self is a requirement. If a pathogen evolved to bind to a host molecule (including 
lipids) and that host molecule had a completely different primary function(s), one would not 
consider such a binding molecule on the host to be a scavenger receptor. Another idea 
proposed included the suggestion that if one of the principal functions of the host molecule 
is to bind pathogens (multiple pathogens), it could be considered a scavenger receptor even 
if there is no evidence for modified self-binding.
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Finally, there were also discussions on whether to include binding specificity and affinity in 
the definition to differentiate various receptors. However, it was determined that this may not 
be appropriate for all scavenger receptors because some scavenger receptors bind some of 
their ligands in the micromolar range, whereas other ligand receptors bind in the nanomolar 
range.
Following the three follow up sessions at Experimental Biology 2014, Immunology 2014, 
and FOCIS 2014, it was decided to keep the original definition agreed upon at the initial 
meeting.
Tables II and III provide the current and revised nomenclature for mouse and human 
scavenger receptors. The following sections provide a brief overview of the currently known 
scavenger receptor classes and the revised nomenclature for each class and member, as 
recommended by the workshop participants and approved in the three follow up sessions 
discussed above.
Class A scavenger receptors: SR-A
Class A scavenger receptors (SR-A) are expressed primarily on tissue macrophages and 
macrophage subtypes such as Kupffer cells and cortical and medullary thymic macrophages 
(33). They have also been observed on high endothelial venules (33) and on subpopulations 
of dendritic cells (34), binding to a variety of foreign and self ligands. Members in this class 
have a similar structure comprised of an N-terminal cytoplasmic tail, transmembrane 
domain, spacer region, α-helical coiled coil domain, collagenous domain, and a C-terminal 
scavenger receptor cysteine-rich (SRCR) domain. SRCR domains are ∼ 100–110 aa long, 
with 6–8 conserved cysteines predicted to form 3–4 disulfide bonds that are present in 
varying numbers in a variety of host defense-related proteins, including different classes of 
scavenger receptors (35, 36). In some cases alternative mRNA splicing deletes the SRCR 
domain. SCARA1/MSR1, the prototypical SR-A molecule, was the first scavenger receptor 
to be cloned and was initially isolated from bovine lung mRNA. It has subsequently been 
identified in other species, including mice and humans. There are three isoforms, which are 
alternative splice variants of the same gene that have been identified, namely, SR-AI, SR-
AII, and SR-AIII (15, 16, 37, 38). Other members of this class of scavenger receptors 
include macrophage receptor with collagenous structure (MARCO), scavenger receptor A 5 
(SCARA5), and scavenger receptor with C-type lectin domain (SRCL-I/II), also designated 
collectin, from placenta receptor-I (28, 39, 40).
The scavenger receptor currently designated as SCARA1 or MSR1 will now be referred to 
as SR-A1. SR-A1 is predominantly found in macrophages, monocytes, mast cells, and 
dendritic cells in both mice and humans (41). A diverse array of ligands is recognized by 
members of this class. SR-A1 binds to β-amyloid (42), heat shock proteins (43), surface 
molecules of Gram-positive and Gram-negative bacteria (17, 44), hepatitis C virus (38), and 
modified LDL such as acetylated LDL (termed AcLDL) and oxidized LDL (OxLDL), but 
not native LDL (15, 16).
SR-A1.1, an alternatively spliced form of SR-A1 (currently referred to as SR-AII), is 
characterized by a shortened C terminus. SR-A1.2, another alternatively spliced form of SR-
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A1 (currently referred to as SR-AIII), is characterized by a truncated C terminus and 
remains trapped in the endoplasmic reticulum. The collagenous region of SR-A1 and SR-
A1.1 has been identified as a major site of polyanionic ligand binding (45). There will be no 
receptor designated as SR-A2 to avoid confusion with the current SR-AII (new designation 
is: SR-A1.1).
Although SR-A1 and SR-A6 (currently known as MARCO) are primarily expressed in 
macrophages, SR-A3 (also referred to as SCARA3, cellular stress response/CSR), SR-A4 
(SCARA4, SRCL, collectin placenta 1/CL-P1), and SR-A5 (SCARA5) are expressed in a 
variety of other tissues and cell types, including the lung, placenta, intestine, heart, and 
epithelial cells (46). SR-A3 has been associated with protecting cells from the detrimental 
effects of reactive oxygen species (21). SR-A4 functions both as an endocytic receptor for 
lipoproteins and mediates the recognition, internalization, and degradation of oxidatively 
modified LDL by vascular endothelial cells (47). SR-A5 (currently known as SCARA5) 
expression is restricted to epithelial cells within the testis, airway, thymus, and the adrenal 
gland. SR-A5 has the capacity to bind bacteria and may play an important role in host 
defense (27). Under normal conditions, in the absence of inflammation, the expression of 
SR-A6 is restricted to macrophages in the lymph nodes and marginal zone of the spleen. 
Studies have shown that SR-A6 mediates the clearance of bacteria from the lungs (48) and 
bloodstream (49).
Consensus member nomenclature
SR-A1. The protein is currently known as MSR1, SR-AI, or SCARA1 [prototype]; 
the current gene name is SCARA1.
SR-A1.1. The protein is currently known as SR-AII. This is an alternatively spliced 
form of SR-A1. There will be no receptor designated as SR-A2. This exception was 
agreed upon during the meeting to avoid confusion with the current SR-AII, which 
will now be designated as SR-A1.1.
SR-A3. The protein is currently known as MSRL1 or APC7; the current gene name is 
SCARA3.
SR-A4. The protein is currently referred to as scavenger receptor C-type lectin 
(SRCL) or CL-P1; the current gene name is COLEC12.
SR-A5. The protein is currently known as TESR; the current gene name is SCARA5.
SR-A6. The gene name is MARCO; the alternative name is SCARA2. The workshop 
participants recommended that the gene name be changed to SCARA6 for 
consistency.
Class B scavenger receptors: SR-B
Class B scavenger receptors include receptors currently known as SR-BI, and its 
alternatively spliced isoform SR-BII, as well as CD36 and LIMP2. Receptors belonging to 
this class are characterized by two transmembrane domains flanking an extracellular loop, 
with both the amino and C termini located within the cytoplasm. The extracellular domain of 
these receptors is extensively N-linked glycosylated, and this modification provides 
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protection against proteases often found in inflammatory sites. CD36 is the prototype class 
B type scavenger receptor and was initially identified as a receptor for thrombospondin (50). 
In this capacity, it modulates angiogenesis and cell-to-cell interactions. It is one of the most 
widely studied scavenger receptors and is involved in multiple aspects of macrophage 
biology, including migration and signaling and inflammatory processes such as foam cell 
formation. CD36 also plays an important role in the host immune response to fungi and 
bacteria and binds erythrocytes infected with the malaria parasite, Plasmodium falciparum 
(51), and it also functions as a facilitator of long-chain fatty acid uptake (52). It is expressed 
in many cell types, including insulin-responsive cells, hematopoietic cells such as platelets, 
monocytes, and macrophages, endothelial cells, and specialized epithelial cells in the breast 
and eye. Endemann et al. (31) were the first to characterize CD36 as a receptor for OxLDL, 
thereby cementing its role as a scavenger receptor. CD36 also binds polyanionic ligands of 
both mammalian hosts (e.g., high-density lipoprotein [HDL]) (53) and pathogens (e.g., 
Staphylococcus aureus and Candida albicans) (20, 54), and plays an important role in the 
recognition and endocytic uptake of oxidized phospholipids, apoptotic cells, and amyloid 
proteins (20). Stewart and colleagues (55) have shown that CD36 (proposed name SR-B2) 
cooperates with TLR family members (TLR4 and TLR6) to activate the innate immune 
response to ligands that accumulate in Alzheimer’s disease and atherosclerosis, inducing 
proinflammatory mediators such as IL-1β and RANTES.
SR-B1 (also known as SCARB1, SR-BI, or CD36L1) was initially cloned as a modified 
LDLR that could also bind unmodified LDL (56) and, together with CD36 (SR-B2), was the 
first surface receptor shown to bind anionic phospholipids (57). It was subsequently shown 
to be the first HDL receptor to be identified and to mediate the selective transport of lipids, 
such as cholesteryl esters from HDL, from circulating lipoproteins into cells (58, 59). SR-B1 
is most highly expressed by hepatocytes and steroidogenic cells, but is also found in cells 
within the arterial wall and macrophages, such as those in human and murine atherosclerotic 
lesions (60). SR-B1 has been shown to have a protective effect on atherosclerosis 
development; total body ablation of SR-B1 in apoE-knockout mice fed a normal chow diet 
led to severe coronary arterial atherosclerosis, myocardial infarction, and death (61). 
Ablation of SR-B1 in bone marrow cells of LDLR knockout mice also resulted in increased 
atherosclerosis, but not death, indicative of partial protection against atherosclerosis (62).
SR-B2, an alternatively spliced form of SR-B1 expressed at substantially lower levels than 
SR-B1, contains a distinctly different cytoplasmic tail from SR-B1. SR-B2 is expressed in 
adrenal glands, testes, and liver, and has been shown to mediate selective uptake of 
cholesteryl ester from HDL with ∼4-fold lower efficiency than SR-B1 (63).
Consensus member nomenclature
SR-B1. The protein is currently also known as SR-BI or CD36L1; the gene name is 
SCARB1.
SR-B1.1. This is an alternatively spliced form of SR-B1, currently known as SR-BII.
SR-B2. The protein is currently known as CD36, SCARB3, or PAS4 [prototype].
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Class C scavenger receptors
Class C scavenger receptors have been described in Drosophila (5), but there are currently 
no known mammalian class C scavenger receptors. This scavenger receptor class was not 
discussed because the workshop focused on mammalian scavenger receptors.
Class D scavenger receptors: SR-D
CD68 is the only member of the class D scavenger receptors. CD68, also known as 
macrosialin in mouse and by other names in mice and humans (Tables II, III), is a type I 
transmembrane glycoprotein that belongs to the lysosome-associated membrane protein (or 
LAMP) family of molecules (64). There is a 300 aa extracellular domain that is rich in 
threonine and serine, which may serve as attachment sites for carbohydrates. It has a short 
cytoplasmic tail. Human CD68 shares 75% aa sequence identity with mouse CD68 in the 
extracellular domain. CD68 is found on monocytes and tissue-specific macrophages in the 
peritoneum, lungs, liver, spleen, Langerhans cells, and microglia, and serves as a scavenger 
receptor for OxLDL (65). CD68 is a differentiation marker of hematopoietic cells of the 
monocyte/macrophage lineage. It is mostly found in the late endosomal compartment in 
macrophages and dendritic cells, with limited expression on resting cells. CD68 plays a 
minor role in the binding and uptake of oxidized lipoproteins and apoptotic cells by 
macrophages (23).
Consensus member nomenclature
SR-D1. The protein is currently known as CD68 [prototype]; the gene name is CD68 
molecule.
Class E scavenger receptors: SR-E
Class E scavenger receptors are type 2 transmembrane proteins with C-type lectin-like 
domains and demonstrated scavenger receptor activity; sequence homology alone is not 
sufficient to include a protein in this class of receptors. Based upon their structure, these 
proteins belong to a subfamily of the NK cell C-type lectin-like (CLEC) receptor family. 
The NK receptor gene complex encodes a large number of CLEC-like receptors that are 
expressed on NK cells and other leukocytes. Analysis of the NK receptor gene complex in 
five species revealed variations in the sizes of the gene clusters: human (29 genes), dog (22 
genes), cattle (32 genes), rat (75 genes), and mouse (57 genes) (66). Among these gene 
clusters, the first two members of the CLEC family, LOX-1 and dectin-1, have been well 
characterized and shown to have scavenger activity.
Lectin-like oxidized LDLR (LOX-1) is expressed on macrophages and dendritic cells, and 
binds oxidized LDL and the acute phase protein C-reactive protein (or CRP) (67). It was 
originally cloned from a bovine aortic endothelial cDNA expression library screened for 
receptors for oxidized LDL (68). LOX-1 is expressed on vascular endothelial cells, platelets, 
smooth muscle cells, adipocytes, and macrophages. In addition to binding oxidized LDL, 
LOX-1 has been implicated in recognizing other ligands, including apoptotic cells, and 
Gram-positive and Gram-negative bacteria (23, 67). A splicing variant of human LOX-1 
lacking a lectin-like domain, called LOXIN, can act as a dominant negative isoform forming 
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a heterodimeric complex with LOX-1 (69). There are no data that this splicing variant is 
present in mouse cells.
Dectin-1 is expressed predominantly on myeloid cells (macrophages, dendritic cells, and 
neutrophils), and can be regulated by cytokines and microbial stimuli. Human dectin-1 is 
alternatively spliced, resulting in two functional forms. This receptor recognizes various 
bacterial, fungal, and plant carbohydrates (β-1,3 and/or β1-6 glucans) in addition to intact 
fungi and parasites (70). Dectin-1 mediates proinflammatory cytokine production in 
response to β-glucan particles, in conjunction with TLR2. It can also function as a 
phagocytic receptor through both Syk-dependent and Syk-independent pathways (71). 
Dectin-1 has been reported to act as a costimulatory molecule to activate both CD4 and CD8 
T cells. Moreover, dectin-1 is expressed on macrophages and dendritic cells in the medullary 
regions of the thymus, suggesting a role in thymocyte development (72).
Some CLEC family members are known to recognize pathogen-associated molecules. 
However, most of the members of the CLEC family have not been shown to have scavenger 
receptor activity. At this time, only LOX-1 and dectin-1 can be classified as scavenger 
receptors using the definition proposed by the workshop participants.
Mannose receptor (CD206)
The human mannose receptor, CD206 (SR-E3), is a 175 kDa transmembrane glycoprotein 
characterized by eight C-type lectin carbohydrate recognition domains. Depending on the 
particle size and the cell type expressing the receptor, it may be involved in phagocytosis of 
mannose-coated particles, in endocytosis of mannosylated glycoproteins, or in receptor-
mediated facilitated Ag presentation. Multiple roles of SR-E3 have been observed. As a 
pattern recognition receptor, SR-E3 recognizes glycans on the surface of pathogenic 
microorganisms, internalizes them via phagocytosis, and transports them to lysosomes for 
degradation. Cells isolated from skin, bone marrow, thymus, lymph node, and peripheral 
blood have demonstrated that SR-E3 is a differentiation marker of immature monocyte-
derived dendritic cells. Studies have shown that inflammatory dendritic epidermal cells that 
are found in inflammatory skin diseases such as atopic dermatitis express the mannose 
receptor, SR-E3. These results suggest that SR-E3 expression in the epidermis may play an 
important role in capturing mannosylated Ags for subsequent Ag presentation (73). Other 
studies have shown that mannose receptors may also play a role in regulating the levels of 
molecules such as myeloperoxidase that are released in response to invading pathogenic 
microorganisms. SR-E3 may then remove these glycoproteins from the circulation to prevent 
damage to host tissues.
Asialoglycoprotein receptor 1 (ASGPR1)
The asialoglycoprotein receptor (ASGPR), also termed the hepatic binding protein or the 
Ashwell receptor, was discovered over four decades ago as a hepatocellular surface receptor 
that binds glycoproteins lacking terminal sialic acid residues (asialoglycoproteins) (74, 75). 
Subsequently, many studies have led to the detailed characterization of the ASGPR, 
describing its functional role in the binding, internalization and transport of a wide range of 
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glycoproteins that have galactose or N-acetylgalactosamine residues via the process of 
receptor-mediated endocytosis (75–78). More specifically, it has been demonstrated that the 
ASGPR can bind a variety of clinically important plasma proteins that include transferrin 
(79), Igs including IgA (80), apoptotic cells (81), fibronectin (82, 83), enzymes such as 
alkaline phosphatase (84, 85), and immune cells (86, 87). The role of ASGPRs as a major 
liver clearance/scavenger mechanism in disease states remains a topic of current research 
efforts.
Several laboratories have investigated the relationship between altered ASGPR function and 
specific mechanisms involved in the pathogenesis of liver disease. Studies examining 
translatable consequences of altered hepatic clearance/scavenging mechanisms revealed that 
liver damaging mechanisms such as aberrant apoptotic cell regulation and innate immune 
defenses were associated with impaired ASGPR function. Particularly, it was shown that 
ethanol-mediated impairments in ASGPR clearance of apoptotic cells could be related to 
enhancements of proinflammatory mechanisms during liver disease (88, 89). Additionally, it 
was found that ethanol-mediated alterations to ASGPRs led to defective hepatocyte killing 
of T cells, which could impact liver immunologic homeostasis and be related to the 
accumulation of lymphocytes, especially CD8+ T cells, that occurs during alcoholic hepatitis 
(90, 91). And more recently, it was determined that impaired ASGPR function due to 
alcohol resulted in altered uptake and trafficking of alkaline phosphatases, leading to 
defective detoxification of LPS and enhanced inflammatory liver injury (92, 93).
These findings indicate that proper functioning of the ASGPR may mediate universal 
protective mechanisms against liver injury by removing a range of desialylated proteins from 
the circulation (94), demonstrating the physiological importance of this hepatic scavenging 
receptor system. Moreover, it is clear that there is an association between altered ASGPR 
function and the progression of liver disease. Further characterization of ASGPR’s 
contribution in liver disease mechanisms could bring forth a better understanding and the 
potential development of successful therapeutic options for liver disease patients.
Consensus member nomenclature
SR-E1. The protein is currently known as LOX-1; the gene name is OLR1: oxidized 
LDLR 1.
SR-E1.1. An alternatively spliced form of SR-E1, the protein is known as LOXIN (no 
known scavenger receptor activity but works as a dominant negative form).
SR-E2. The protein is currently known as dectin-1; the gene name is CLEC7A.
SR-E3. The protein is currently known as mannose receptor 1, CD206, or MRC1; the 
gene name is mannose receptor C type 1.
SR-E4. The protein is currently known as ASGPR1, CLEC4H1, or HL-1; the gene 
name is ASGR1.
Class F scavenger receptors: SR-F
There are currently three members belonging to the class F scavenger receptors. The first 
class F scavenger receptor (SCARF or SCARF1) was identified as an endothelial receptor 
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for modified LDL, and is characterized by the presence of an extracellular ligand-binding 
domain, with multiple extracellular epidermal growth factor–like repeats, a transmembrane 
domain, and a long cytoplasmic tail that includes a serine/proline-rich region followed by a 
glycine-rich region and is rich in positively charged residues (38). It was named scavenger 
receptor expressed by endothelial cells (SREC or SREC-I) (95). SCARF1/SREC-I is also 
expressed in macrophages, and functions to bind calreticulin and associated peptides, which 
are transported into the MHC class I pathway in macrophages and dendritic cells (23). 
SCARF1 is also a receptor for fungal pathogens and heat shock proteins (20, 38). 
Interestingly, a Caenorhabditis elegans ortholog of SCARF1, CED-1, plays a role in 
engulfing apoptotic cells and has been implicated in host defense (23). A recent report 
indicates that SCARF1, similar to CED-1, participates in the clearance of apoptotic cells 
(96).
SREC-II, also known as SCARF2, was isolated by Ishii et al. (97) in 2002. Although SREC-
II, like SREC-I, was initially identified on endothelial cells, SREC-II is also expressed on 
macrophages. SREC-II can bind to SREC-I in trans (97), but a scavenger receptor function 
for SREC-II has not yet been reported.
Another member of the SCARF family, multiple EGF-like domains-10 (MEGF10), recently 
has been shown to be a receptor for the protein amyloid-β in the brain, and is thought to be 
involved in the pathogenesis of Alzheimer’s disease (23). Recently, MEGF10 has been 
shown to be a receptor for the complement protein C1Q and consequently to mediate the 
clearance of apoptotic cells in the developing mouse cerebellum (98). Mutations in MEGF10 
in humans result in early-onset myopathy, areflexia, respiratory distress, and dysphagia 
(EMARDD). These EMARDD mutations also have a defect in binding C1Q (98). Whether 
such a defect is related to the clinical presentation of EMARDD patients is not known. It is 
not clear yet whether other MEGF family members, such as MEGF8, 9, and 11, also have a 
scavenger receptor function, because no functional studies have been published to date on 
these molecules.
Consensus member nomenclature
SR-F1. The protein is currently known as SREC-I/SCARF1 [prototype]; the gene 
name is SCARF1.
SR-F2. The protein is currently known as MEGF10.
Class G scavenger receptors: SR-G
Currently, one receptor belongs to scavenger receptor class G, SR-PSOX/CXCL16. 
Shimaoka et al. (99) used expression cloning from a cDNA library of PMA-treated human 
monocytic THP-1 cells to identify scavenger receptors that bound OxLDL, and discovered 
this receptor, which they called SR-PSOX (scavenger receptor that binds phosphatidylserine 
and oxidized lipids). At around the same time, the groups of Dr. Jason Cyster and Dr. 
Michael Briskin discovered a new chemokine that was capable of activating CXCR6 (also 
known as BONZO, STRL33, or TYMSTR), resulting in migration of T cells in vitro (100–
102). This chemokine was named CXCL16 and was found to be identical to SR-PSOX in its 
amino acid sequence.
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Studies show that the SR-PSOX/CXCL16 gene is located on chromosome 17p13, and its 
protein exists in both membrane and soluble forms (100). It is a type I transmembrane 
glycoprotein with a CXC chemokine motif, mucin stalk, transmembrane, and extracellular/
soluble domains. SR-PSOX/CXCL16 does not share structural similarity with other 
scavenger receptors. SR-PSOX/CXCL16 has the capacity to mediate adhesion and 
phagocytosis of bacteria by APCs (101). The membrane-bound form can function as an 
adhesion molecule for CXCR6-expressing T cells without requiring CXCR6-induced signal 
transduction and integrin activation.
This multifunctional transmembrane protein has a chemokine-like CXC motif and appears to 
be involved in several phases of an immune response from Ag recognition to migration of 
immune cells to formation of inflammatory foci (103). The soluble form of SR-PSOX/
CXCL16, produced by cleavage from the membrane domain, functions as a chemoattractant 
for activated T cells and bone marrow plasma cells via its receptor CXCR6 (104). The 
membrane-bound form acts as a scavenger receptor for OxLDL, and facilitates phagocytosis 
of bacteria by APCs (104).
Consensus member nomenclature
SR-G1. The protein is currently known as SR-PSOX/CXCL16 [prototype]; the gene 
name is CXCL16.
Class H scavenger receptors: SR-H
Receptors in this class are transmembrane proteins that consist of fasciclin, EGF-like, and 
lamin-type EGF-like (FEEL) domains. The currently known proposed SR-H group members 
are FEEL-1/stabilin-1/CLEVER-1, and FEEL-2/stabilin-2/HARE. FEEL-1 is predominantly 
expressed in macrophages, mononuclear cells, hematopoietic stem cells, and endothelial 
cells, whereas FEEL-2 is found mainly in sinusoidal endothelial cells. FEEL-1 and FEEL-2 
have been shown to be involved in lymphocyte adhesion, transmigration, angiogenesis, 
apoptotic cell clearance, and intracellular trafficking. FEEL-1 and FEEL-2 also have been 
implicated in the clearance of aged RBCs by macrophages (105, 106) in a 
phosphatidylserine-dependent manner. FEEL-1 has been shown to directly interact with and 
phagocytose phosphatidylserine-coated beads, but this action has yet to be confirmed in 
vivo. However, FEEL-1 and FEEL-2 double knockout mice have been shown to have 
impairment in the clearance of noxious blood factors (107).
Consensus member nomenclature
SR-H1. The protein is currently known as FEEL-1, stabilin-1, or CLEVER-1 
[prototype]; the gene name is STAB1.
SR-H2. The protein is currently known as FEEL-2, or stabilin-2; the gene name is 
STAB2.
Class I scavenger receptors: SR-I
The CD163 family of molecules are type I transmembrane receptors characterized by 
multiple group B SRCR domains in their extracellular domain, with membrane proximal 
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SRCR domains in a conserved b-c-d-e-d′ cassette organization. The structure of each SRCR 
domain, modeled on the CD5 group B SRCR domain crystal structure (108), offers potential 
binding sites on aqueous-accessible loops, β strands, an α helix, and in a hydrophobic 
cavity. CD163A, the prototypic proposed class I scavenger receptor, is expressed exclusively 
by monocytes and macrophages and binds to haptoglobin-hemoglobin complexes to promote 
the clearance of plasma hemoglobin via endocytosis during intravascular hemolysis. 
CD163A is a type I transmembrane protein consisting of an extracellular domain composed 
of nine SRCR domains and a short cytoplasmic tail. CD163A was originally cloned from the 
spleen of a patient afflicted with hairy cell leukemia, characterized by a large number of 
tissue macrophages. It is a 130 kDa membrane glycoprotein, and was known as M130 prior 
to being given a CD designation. CD163A was also given a functional name, “hemoglobin 
scavenger receptor” to describe its primary role in tissue macrophages (109). Its role as a 
hemoglobin receptor may contribute to enhancement of an anti-inflammatory response 
because the proinflammatory heme is converted to anti-inflammatory metabolites (110).
In addition to functioning as an hemoglobin receptor, CD163A binds Gram-negative and 
Gram-positive bacteria via an outside loop (111). It appears to be involved in intracellular 
signaling via protein kinases, causing secretion of cytokines such as IL-6 and IL-10 (112). 
Several CD163A mRNAs arising from alternatively spliced CD163 gene transcripts have 
been reported (109, 112). Confocal microscopy studies revealed that the variant with the 
shortest tail is predominantly present in the cell membrane, whereas the variants with the 
longer tails are located in the endosomal/Golgi cellular compartment (112). One short tail 
variant and two long tail variants have been shown to bind and internalize haptoglobin-
hemoglobin complexes leading to lysosomal degradation of the complex (112). The short 
tail variant is the predominant isoform found in human blood, liver, and spleen, whereas the 
majority of the long tail variants appear in endosomal compartments (112).
CD163-L1 (M160, CD163B, encoded by CD163L1), a long tail homolog of CD163A, is a 
type I transmembrane molecule structurally composed of 12 SRCR domains, expressed by 
cells of the myeloid lineage, and may be involved in the differentiation of monocytes to 
macrophages. Thus far, it has only been found in the human and equine genomes (113). Two 
cytoplasmic splice variants of CD163-L1 have been identified thus far: the full-length 
variant (CD163-L1α) with a cytoplasmic tail of 71 aa residues and the short tail variant 
(CD163-L1β) with 39 aa residues. CD163-L1α is the predominant membrane-associated 
form in several human tissues such as spleen, placenta, and small intestine, whereas CD163-
L1β is mainly found in intracellular compartments (114). Studies to identify endogenous and 
microbial ligands of CD163-L1β are currently in progress.
The third human CD163 family molecule is CD163c-α (CD163-L1 or hSCART1). It is a 
type I transmembrane molecule characterized by an extracellular domain with five SRCR 
domains, a transmembrane domain, and a cytoplasmic domain containing tyrosine and 
serine phosphorylation motifs as well as a dileucine endocytic motif. Alternatively spliced 
isoforms include one with two SRCR domains, a transmembrane and cytoplasmic domain, 
and one with four SRCR domains that are predicted to be secreted. It is expressed by αβ and 
γδ T cells and in the small intestine and colon (115). The murine genome encodes two 
CD163c-α genes, SCART1 and SCART2, which are expressed on γδ T cells, and in the 
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lymph node, trachea, and lung. The bovine genome contains one CD163 gene and one 
CD163c-α/SCART1 gene, which are both expressed in γδ T cells, as well as peripheral 
blood monocytes, mesenteric lymph node, lung, and intestinal epithelial lymphocytes (113).
In addition to the class I scavenger receptors expressed in humans (CD163A, CD163b, and 
CD163c-α/SCART1), other mammalian species also express a closely related molecule 
WC1 (T19) (113). In species examined thus far, WC1 is encoded in duplicated multigenic 
arrays. The bovine genome has 13 WC1 genes (116, 117). Twelve of the bovine WC1 genes 
encode 11 SRCR domains; one encodes six SRCR domains in the extracellular domain. All 
WC1 molecules are type I transmembrane receptors with a signal peptide, SRCR domains in 
the extracellular domain organized into the b-c-d-e-d′ cassette that has been conserved in 
the CD163 family, a transmembrane domain, and a cytoplasmic domain (117, 118). Table IV 
provides the nomenclature for the bovine scavenger receptors. In the bovine, WC1 is only 
expressed on γδ T cells where it serves as a hybrid coreceptor and pattern recognition 
receptor in the γδ T cell memory response to bacteria (119–121). Coreceptor signaling 
through WC1 and TCR is dependent on the phosphorylation of tyrosines and serines in the 
WC1 cytoplasmic domain, and is downregulated by endocytosis via a WC1 dileucine motif 
(119–121). Individual WC1 SRCR domains from selected WC1 molecules bind to the 
bacteria Leptospira spp., Borrelia burgdorferi, and Mycobacteria spp., suggesting that the 
natural selection pressure necessary to maintain multiple WC1 open reading frames is 
derived from the specificity for diverse pathogens of individual WC1 molecules (122).
Of note, WC1 receptors are not the only scavenger receptors expressed in bovine tissues. As 
mentioned earlier, SR-A, SR-E, and SR-J were initially cloned from bovine lung and 
endothelial cells, respectively. Table IV refers only to scavenger receptors exclusively 
described in bovine tissues.
Consensus member nomenclature—The proposed definition for this group is 
transmembrane proteins with multiple SRCR domains.
SR-I1. The protein is currently known as CD163A or M130 [prototype]; the gene 
name is CD163.
SR-I1.1. The protein is the CD163 long tail variant 1.
SR-I1.2. The protein is the CD163 long tail variant 2.
SR-I2. The protein is currently known as CD163B or M160; the gene name is 
CD163L1.
SR-I3. The protein is currently known as CD163c-α or SCART1; the gene name is 
cd163l1.
SR-I4. The protein is currently known as murine SCART2.
SR-I5 to SR-I17. The proteins currently correspond to bovine WC1-1 to WC1-13.
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Class J scavenger receptors: SR-J
The receptor for advanced glycation end products (RAGE) is currently the only member of 
the class J scavenger receptor group. It is a member of the Ig superfamily of cell surface 
molecules capable of interacting with a broad spectrum of ligands, including advanced 
glycation end products, high mobility group protein box-1 (HMGB1), and the S-100 protein. 
RAGE is composed of a single transmembrane domain that connects the amino-terminal 
ligand recognition and binding ectodomain with a short cytoplasmic domain. The 
extracellular domain also contains three Ig-like regions. RAGE is a pattern recognition 
receptor predominantly involved in the recognition of endogenous molecules released in the 
context of infection, physiological stress, or chronic inflammation (123). Signaling through 
RAGE mediates processes such as inflammation, oxidative stress, and apoptosis, which can 
lead to pathologies including atherosclerosis, diabetes, cancer, neurodegenerative disease, 
and stroke (124). RAGE signaling also mediates developmental processes in neurons such as 
cell migration and differentiation. However, studies assessing brain pathology in 
Alzheimer’s disease revealed that diseased brains express higher levels of RAGE in the 
vasculature and on neurons compared with normal brains (23). In addition to the membrane-
bound form, a circulating portion of the protein, known as “soluble” RAGE (termed sRAGE) 
also has biological properties. Elevated levels of soluble RAGE and HMGB1 expression 
were observed in patients with myocarditis compared with healthy controls (125). Moreover, 
RAGE-deficient mice were observed to be protected from developing troponin I–induced 
autoimmune myocarditis, with a concomitant decrease in several inflammatory mediators 
(126).
Consensus member nomenclature
SR-J1. The protein is currently known as the membrane-bound form of RAGE/
AGER; the gene name is AGER.
SR-J1.1. This terminology will be used to designate the soluble form of RAGE.
Class K scavenger receptors: SR-K
Several lines of evidence suggest that CD44, a cell surface glycoprotein best known as a 
receptor for hyaluronan, should be included within the family of scavenger receptors.
Although CD44 is not structurally homologous to any of the known scavenger receptors, it 
nonetheless shares structural features in common with them. It is a multidomain, single-span 
transmembrane protein with only a modest cytosolic tail with limited direct signaling 
capabilities (127). The N-terminal extracellular domain consists of motifs that serve as 
docking sites for various ligands that include hyaluronan, extracellular matrix glycoproteins 
and proteoglycans, growth factors, cytokines, and matrix metalloproteinases. The C-terminal 
cytoplasmic tail binds to cytoskeletal elements and interacts with signaling molecules, which 
are members of the Src family kinases (128). Like other scavenger receptors, it is susceptible 
to shedding by exofacial proteases (129) and these cleavage products are thought to be 
biologically active (130).
CD44 also has functional properties in common with other scavenger receptors. It has a 
broad repertoire of ligands that include both host (131–133) and microbial (134) molecules. 
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It associates with a diverse range of other proteins, including TGF-βRI (135), CD3 (136), 
TLR 2 (137), and CD14 (138), and thereby engages with multiple intracellular signaling 
pathways, probably through formation of heteromultimeric signaling complexes and 
interactions with the actin cytoskeleton (139). Like other scavenger receptors, it contributes 
to the clearance of its extracellular matrix ligands via endocytosis (140). CD44 also 
contributes to pattern recognition (141) and innate immunity (142). As with other scavenger 
receptors, the pro- and anti-inflammatory contributions of CD44 are highly dependent on 
cell type and context (143–145) Along with its immunologic roles, CD44 also makes 
important, overlapping contributions to cellular migration (146), polarization (147), and 
homeostasis (148).
In light of these structural and functional similarities with other scavenger receptors, we 
have included CD44 as a distinct class of scavenger receptor, class M.
Consensus member nomenclature
SR-K1. The protein is currently known as CD44; the gene name is CD44.
Class L scavenger receptors: SR-L
SR-L1 is one of the largest members of the LDLR gene family (149). It is also known as 
LDLR-related protein 1 (LRP1), α2-macroglobulin receptor (A2MR), or CD91 (150). The 
gene family to which SR-L1 belongs includes as its best known member the LDLR, which 
serves as the principal clearance receptor for plasma cholesterol. The first members of this 
ancient family likely appeared with the first metazoans, as they are present in the most 
primitive multicellular eukaryotic organism that survives on the planet to this day. 
Remarkably, despite being separated from present day mammals by ∼1 billion years of 
evolution, their exon/intron structure has been conserved virtually perfectly throughout time. 
Moreover, within the mammalian kingdom, SR-L1 in particular exhibits a remarkable degree 
of primary amino acid sequence conservation, which further emphasizes the unique 
importance of SR-L1, and several other members of the gene family, that is, LRP1b, LRP2, 
LRP4, LRP8, and very LDLR (termed VLDLR) for the survival of all species (151). LRP2 
is involved in the reuptake of albumin, vitamin D–binding protein, and retinol-binding 
protein. LRP2 is defective in Donnai–Barrow syndrome (152).
Although LRP1/SR-L1 and other family members have been investigated intensely for a 
quarter century, we still do not have a complete understanding of all their biological 
functions. Rather than transmitting an extracellular signal across the membrane itself, SR-L1 
mostly regulates such signals by serving as an extracellular sensor that detects the presence 
of a myriad of cargo ligands or bioactive molecules in the extracellular space. By modifying 
or integrating signals transmitted through classical signal transducing receptors SR-L1 
serves a double purpose: it clears and removes—or scavenges—the ligands from the surface 
or extracellular space and, at the same time, the presence of these ligands modifies the 
signals sent to the interior of the cell by the associated classical signal transduction 
receptors. In this way, the cell can receive a variety of signals, which include, for instance, 
the activity of extracellular protease activity, cellular adhesion, nutrient availability, and 
growth signals, and which help the cell to determine its status within the tissue and the 
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organism as a whole. Hence, serving as an extracellular sensor and simultaneously as a 
scavenger receptor for the same ligands are merely two faces of the same coin.
Currently, over 100 functionally diverse ligands are known to interact with LRP1/SR-L1. 
Many of them have also been found to bind to LRP1b and to LRP2, both closely related 
family members of similar size, but different tissue distribution. For most of these ligands, 
the exact biological conditions that are regulated by their receptor interactions, and in 
particular the coreceptors or signal transducers whose functions they modulate, remain 
unknown. Only some of these functions are briefly listed here and they include limb and 
brain development, synaptic homeostasis and amyloid clearance and removal (153), liver 
lipid and energy metabolism, synaptic transmission, thrombosis, hemostasis, the protection 
of vascular integrity by regulating reverse cholesterol transport, fibrosis and smooth muscle 
cell proliferation (154), regulation of the inflammatory response (e.g., through TLRs and 
defensins), and others (155).
Megalin (SR-L2), also known as LRP2, is a multiligand endocytic receptor that belongs to 
the LRP family of proteins. It is a large membrane glycoprotein that belongs in the LDLR 
family. It is expressed on the apical membrane of several epithelial cells such as kidney 
proximal tubule cells, lung, thyroid, gallbladder, and neuroepithelium, as well as steroid-
responsive tissues such as epididymis, prostate, ovaries, and uterus (156, 157). The 
cytoplasmic domain is small and has been suggested to regulate its endocytic activities 
(158). SR-L2 is expressed at the blood brain barrier where it binds and internalizes a variety 
of ligands such as leptin, insulin, and amyloid β peptide (157). Mice that lacked 
megalin/SR-L2 in brain endothelial cells exhibited neurodegeneration and 
neuroinflammation, as well as obesity (157). Evidence has also been demonstrated for the 
role of peroxisome proliferator-activated receptors (termed PPARs) in regulating the 
expression of SR-L2 (158).
Consensus member nomenclature
SR-L1. The protein is currently known as LDLR-related protein 1 (LRP1). It is also 
known as α2-macroglobulin receptor (A2MR), apolipoprotein E receptor (APOER) 
or CD91; the gene name is Lrp1.
SR-L2. The protein is currently known as megalin or gp330; the gene name is Lrp2.
Other potential scavenger receptors: SR-Others
The SR-Others group refers to molecules with scavenger activity that do not belong to the 
current scavenger receptor classes, but belong to other receptor families. These receptors 
include CD11b/CD18α. Classifying these receptors as scavenger receptors will require the 
input of the wider scientific community.
Another receptor that may be considered for inclusion as a scavenger receptor is CD14. 
CD14 is a GPI-linked protein found on monocytes and polymorphonuclear leukocytes. 
CD14 has a binding site for amphipathic molecules such as LPS and lipidated microbial cell 
wall fragments, as well as phosphatidylcholine, phosphatidylinositol, and other endogenous 
phospholipids. Binding of amphiphiles to CD14 is readily reversible, allowing cell surface 
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CD14 to transfer the amphiphiles into the plasma membrane bilayer, to MD2 or to TLR4. 
By this means, CD14 can serve as a shuttle for the clearance of amphiphilic molecules. 
Shuttling of bacterial LPS is particularly favored because the plasma protein, LPS-binding 
protein, serves as a lipid transfer protein that specifically transfers LPS monomers into 
CD14. The binding of LPS to CD14 catalyzed by the LPS-binding protein can then be 
followed by transfer of the LPS to MD2 or TLR4 or into the plasma membrane bilayer. 
CD14 thereby fulfills the definition of scavenger receptor by binding multiple ligands and 
serving for their clearance. CD14 may be shed from the surface and appears in plasma and 
other biological fluids at relatively high levels. This soluble CD14 retains the ability to bind 
amphiphiles and retains the ability to serve in the shuttling of lipids.
Receptors that are not included as scavenger receptors
The decision to exclude specific receptors for viruses which facilitate entry of viral particles 
into cells is based on their inability to meet most of the criteria of scavenger receptors. Three 
examples of such receptors are angiotensin-converting enzyme-2 (ACE2), aminopeptidase 
N, which is also known as CD13, and lysosomal integral membrane protein 2 (also known as 
SCARB2 or CD36b like-2).
ACE2 is a type I membrane-bound zinc metallopeptidase. It functions as a 
monocarboxypeptidase that cleaves the C-terminal amino acid from angiotensins I and II as 
well as from several other peptides at its extracellular catalytic domain (159). It is also the 
receptor for the SARS coronavirus (160). Although its peptidase activity is not specific to a 
single peptide substrate or peptide sequence, its function is to metabolize self rather than 
altered-self peptides. In its role as a virus receptor, the only ligand that is reported to bind to 
ACE2 with high affinity is the S1 domain of the SARS virus (160), suggestive of a high 
specificity, as opposed to broad-ligand specificity. Additionally, ACE2 enables the SARS 
virus to enter cells simply by serving in a passive role as an anchor to the cell membrane, 
allowing it to fuse with and penetrate the cell membrane to enter cells. Moreover, this 
internalization allows the virus to proliferate rather than to be eliminated or inactivated as 
would occur with a scavenger receptor.
Aminopeptidase N (CD13, E.C. 3.4.11.2) is a type I membrane-bound zinc metallopeptidase 
that cleaves the amino terminal from angiotensin III, enkephalins, and several other peptides 
at its extracellular catalytic domain (161). It is also the receptor for several coronaviruses: 
229E, transmissible gastroenteritis virus, porcine epidemic diarrhea virus, and feline 
infectious peritonitis virus, which belong to the group I coronaviruses (160, 162). Similar to 
ACE2, its peptidase activity is not specific to a single peptide substrate or peptide sequence, 
and its function is to metabolize self rather than altered-self peptides. In its role as a virus 
receptor, it is still relatively selective, inasmuch as it binds a limited number of class I 
coronaviruses, in contrast to a broad-ligand specificity. Additionally, aminopeptidase N 
enables the viruses to enter cells also serving a passive role as an anchor to the cell 
membrane that allows the viruses to fuse with and penetrate the cell membrane to enter cells. 
As noted above, this internalization allows the virus to proliferate rather than to be 
inactivated, as would occur with a scavenger receptor.
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Lysosomal integral membrane protein 2 (LIMP2, also known as SCARB2 or CD36b like-2) 
is a member of the CD36 superfamily of proteins and is a type III glycoprotein located in the 
membranes of lysosomes and endosomes and contains two transmembrane domains (163). 
Some of its functions include transporting the lysosomal protein glucocerebrosidase from 
the endoplasmic reticulum through the Golgi system to lysosomes where cellular 
degradation occurs (164). Reports have demonstrated that LIMP2 is a receptor for a variety 
of human enteroviruses such as EV71, coxsackievirus (CV) A16, CVA14, and CVA7 (165), 
supporting viral propagation and cytopathic effects. It is not known if LIMP2 has additional 
scavenger receptor like functions. Classifying LIMP2 as a potential scavenger receptor will 
be reassessed if additional information becomes available.
Conclusions
In addition to their functions as phagocytic receptors and innate immune recognition 
receptors, scavenger receptors also play an important role as regulators of inflammatory 
signaling. A schematic representation of the current scavenger receptors classes is provided 
in Fig. 2. These receptors have also been implicated in a number of physiological and 
pathological processes. These include interactions with other innate immune receptors, 
delivery of ligands to different cellular compartments, and Ag presentation. Furthermore, the 
role of these receptors in neurodegenerative diseases, diabetes, and other metabolic 
disorders, and their potential as targets for therapeutic interventions to treat various 
disorders, warrant further study. Having a standardized nomenclature as described herein 
will help to overcome current ambiguities in communication about specific scavenger 
receptors and, perhaps, remove a major barrier for researchers in other fields to enter the 
scavenger receptor field.
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Abbreviations in this article
ACE2 angiotensin-converting enzyme-2
ASGPR asialoglycoprotein receptor
CLEC C-type lectin-like
EMARDD early-onset myopathy, areflexia, respiratory distress and dysphagia
FEEL fasciclin, EGF-like and lamin type EGF-like
HDL high-density lipoprotein
LDL low-density lipoprotein
LDLR LDL receptor
NIAID National Institute of Allergy and Infectious Diseases
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NIH National Institutes of Health
OxLDL oxidized LDL
RAGE receptor for advanced glycation end products
SARS severe acute respiratory syndrome
SRCR scavenger receptor cysteine-rich
SREC scavenger receptor expressed by endothelial cells
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FIGURE 1. 
Proposed scavenger receptor nomenclature formula. SR stands for scavenger receptor. SR is 
followed by a hyphen, then a capital letter represents the class of scavenger receptor (A–J), 
followed by an Arabic numeral representing the type of molecule within the class (the 
numbering is based on the order in which the molecules were identified). Alternatively 
spliced forms of a molecule will be designated as 1.1, 1.2, etc. For existing spliced variants, 
the longest variant in terms of amino acid sequence will be given the first number.
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FIGURE 2. 
Schematic representation of different classes of scavenger receptors. Mammalian scavenger 
receptors are divided into 12 classes. The various protein or carbohydrate domains are 
identified in the key within the figure. Class C is not represented here because it is present 
only in Drosophila melanogaster.
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Table I
Workshop participants and their areas of expertise
Participant Affiliation Area of Expertise
Dawn Bowdish McMaster University, Canada Macrophage scavenger receptors in host defense
Kurt Drickamer Imperial College, U.K. C-type lectin and glycan recognition
Joseph El Khoury Massachusetts General Hospital, Harvard 
Medical School, MA
Macrophage and microglial scavenger receptors in inflammation
Maria Febbraio University of Alberta, Canada CD36 signaling
Joachim Herz University of Texas Southwestern Medical 
Center, TX
Functions of LDLR-related proteins
Lester Kobzik Harvard School of Public Health, MA MARCO and lung inflammation
Monty Krieger Massachusetts Institute of Technology, MA Scavenger receptors in host defense and lipoprotein and lipid 
metabolism
John Loike Columbia University, NY Scavenger receptors in neuropathology
Terry Means Massachusetts General Hospital, Harvard 
Medical School, MA
Scavenger receptors and antifungal immune mechanisms
Soren Moestrup Aarhus University, Denmark Hemoglobin scavenger receptor
Philip Murphy NIAID, NIH, MD G-protein coupled receptors in leukocyte trafficking
Steven Post University of Arkansas for Medical Sciences, AR Scavenger receptor A and atherosclerosis
Tatsuya Sawamura Shinshu University, Japan Oxidized LDLR (LOX-1) and vascular inflammation
Samuel Silverstein Columbia University, NY Roles of scavenger receptors on mononuclear phagocytes in chronic 
inflammatory diseases
Xiang-Yang Wang Virginia Commonwealth University, VA Scavenger receptors in immune modulation and host response
 Cynthia Baldwin University of Massachusetts, Amherst, MA γδ T cells and WC1 coreceptor family in the bovine model
 Paul Bollyky Stanford University, CA Immune dysregulation in wound healing, biofilms
 Benita McVicker University of Nebraska, NE Hepatocellular-lymphocyte interactions
 Robert Speth Nova Southeastern University, FL Regulation of the cardiovascular system
 Janice Telfer University of Massachusetts, Amherst, MA Immune development; characterization of SRCR family of receptors 
in cattle
 Geoffrey Thiele University of Nebraska, NE Peripheral vascular disease, cardiovascular disease, and immune 
tolerance
 Samuel Wright Cardiovascular Therapeutics, PA Cardiovascular disease, atherosclerosis, and inflammation
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